Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Predictors of survival trajectories among women with epithelial ovarian cancer.

Peres LC, Sinha S, Townsend MK, Fridley BL, Karlan BY, Lutgendorf SK, Shinn E, Sood AK, Tworoger SS.

Gynecol Oncol. 2020 Feb;156(2):459-466. doi: 10.1016/j.ygyno.2019.12.011. Epub 2019 Dec 12.

PMID:
31839342
2.

Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. No abstract available.

PMID:
31092618
3.

Cystitis-induced bladder pain is Toll-like receptor 4 dependent in a transgenic autoimmune cystitis murine model: a MAPP Research Network animal study.

Cui X, Jing X, Lutgendorf SK, Bradley CS, Schrepf A, Erickson BA, Magnotta VA, Ness TJ, Kreder KJ, O'Donnell MA, Luo Y.

Am J Physiol Renal Physiol. 2019 Jul 1;317(1):F90-F98. doi: 10.1152/ajprenal.00017.2019. Epub 2019 May 15.

PMID:
31091120
4.

Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.

Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJ.

Psychoneuroendocrinology. 2019 Aug;106:244-251. doi: 10.1016/j.psyneuen.2019.04.007. Epub 2019 Apr 6.

PMID:
31005045
5.

A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study.

Helfand BT, Andreev VP, Siddiqui NY, Liu G, Erickson BA, Helmuth ME, Lutgendorf SK, Lai HH, Kirkali Z; LURN Study Group.

Urology. 2019 Jul;129:35-42. doi: 10.1016/j.urology.2019.03.014. Epub 2019 Mar 25.

PMID:
30922973
6.

Adverse Childhood Experiences and Symptoms of Urologic Chronic Pelvic Pain Syndrome: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Study.

Schrepf A, Naliboff B, Williams DA, Stephens-Shields AJ, Landis JR, Gupta A, Mayer E, Rodriguez LV, Lai H, Luo Y, Bradley C, Kreder K, Lutgendorf SK; MAPP Research Network.

Ann Behav Med. 2018 Sep 13;52(10):865-877. doi: 10.1093/abm/kax060.

7.

Stress effects on FosB and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.

Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK.

J Biol Chem. 2018 Jun 29;293(26):10041. doi: 10.1074/jbc.AAC118.004299. No abstract available.

8.

Stress, inflammation, and eicosanoids: an emerging perspective.

Umamaheswaran S, Dasari SK, Yang P, Lutgendorf SK, Sood AK.

Cancer Metastasis Rev. 2018 Sep;37(2-3):203-211. doi: 10.1007/s10555-018-9741-1. Review.

9.

Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.

Armer JS, Clevenger L, Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Sood AK, Cole SW, Slavich GM, Lutgendorf SK.

Cancer. 2018 Aug;124(16):3401-3408. doi: 10.1002/cncr.31570. Epub 2018 Jun 15.

10.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2018 Jun 7;3(11). pii: 122389. doi: 10.1172/jci.insight.122389. eCollection 2018 Jun 7. No abstract available.

11.

Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study.

Kogan P, Xu S, Wang Y, O'Donnell MA, Lutgendorf SK, Bradley CS, Schrepf A, Kreder KJ, Luo Y.

Sci Rep. 2018 Apr 26;8(1):6573. doi: 10.1038/s41598-018-24833-x.

12.

Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.

Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK.

Cancer Res. 2018 Jun 15;78(12):3233-3242. doi: 10.1158/0008-5472.CAN-16-1701. Epub 2018 Apr 16.

13.

Internet-Based Group Intervention for Ovarian Cancer Survivors: Feasibility and Preliminary Results.

Kinner EM, Armer JS, McGregor BA, Duffecy J, Leighton S, Corden ME, Gauthier Mullady J, Penedo FJ, Lutgendorf SK.

JMIR Cancer. 2018 Jan 15;4(1):e1. doi: 10.2196/cancer.8430.

14.

Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.

Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW.

Cancer. 2018 Feb 1;124(3):580-586. doi: 10.1002/cncr.31078. Epub 2017 Nov 7.

15.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.

JCI Insight. 2017 Aug 17;2(16). pii: 93076. doi: 10.1172/jci.insight.93076. eCollection 2017 Aug 17.

16.

Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer.

Cuneo MG, Schrepf A, Slavich GM, Thaker PH, Goodheart M, Bender D, Cole SW, Sood AK, Lutgendorf SK.

Psychoneuroendocrinology. 2017 Oct;84:139-142. doi: 10.1016/j.psyneuen.2017.06.019. Epub 2017 Jun 30.

17.

Changes in spiritual well-being and psychological outcomes in ovarian cancer survivors.

Davis LZ, Cuneo M, Thaker PH, Goodheart MJ, Bender D, Lutgendorf SK.

Psychooncology. 2018 Feb;27(2):477-483. doi: 10.1002/pon.4485. Epub 2017 Aug 4.

18.

Social well-being is associated with less pro-inflammatory and pro-metastatic leukocyte gene expression in women after surgery for breast cancer.

Jutagir DR, Blomberg BB, Carver CS, Lechner SC, Timpano KR, Bouchard LC, Gudenkauf LM, Jacobs JM, Diaz A, Lutgendorf SK, Cole SW, Heller AS, Antoni MH.

Breast Cancer Res Treat. 2017 Aug;165(1):169-180. doi: 10.1007/s10549-017-4316-3. Epub 2017 May 30.

19.

Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.

Lutgendorf SK, Shinn E, Carter J, Leighton S, Baggerly K, Guindani M, Fellman B, Matzo M, Slavich GM, Goodman MT, Tew W, Lester J, Moore KM, Karlan BY, Levine DA, Sood AK.

Gynecol Oncol. 2017 Jul;146(1):101-108. doi: 10.1016/j.ygyno.2017.05.008. Epub 2017 May 17.

20.

SSRI use and clinical outcomes in epithelial ovarian cancer.

Christensen DK, Armaiz-Pena GN, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D, Thaker PH, Ahmed A, Penedo FJ, DeGeest K, Mendez L, Domann F, Sood AK, Lutgendorf SK.

Oncotarget. 2016 May 31;7(22):33179-91. doi: 10.18632/oncotarget.8891.

21.

Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.

Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA.

Gynecol Oncol. 2016 May;141(2):260-263. doi: 10.1016/j.ygyno.2016.03.010. Epub 2016 Mar 11.

22.

SnapShot: Stress and Disease.

Nagaraja AS, Sadaoui NC, Dorniak PL, Lutgendorf SK, Sood AK.

Cell Metab. 2016 Feb 9;23(2):388-388.e1. doi: 10.1016/j.cmet.2016.01.015.

23.

Role of Increased n-acetylaspartate Levels in Cancer.

Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK.

J Natl Cancer Inst. 2016 Jan 26;108(6):djv426. doi: 10.1093/jnci/djv426.

24.

Inflammation and Symptom Change in Interstitial Cystitis or Bladder Pain Syndrome: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Study.

Schrepf A, O'Donnell MA, Luo Y, Bradley CS, Kreder KJ, Lutgendorf SK.

Urology. 2016 Apr;90:56-61. doi: 10.1016/j.urology.2015.12.040. Epub 2016 Jan 6.

25.

Biofield Physiology: A Framework for an Emerging Discipline.

Hammerschlag R, Levin M, McCraty R, Bat N, Ives JA, Lutgendorf SK, Oschman JL.

Glob Adv Health Med. 2015 Nov;4(Suppl):35-41. doi: 10.7453/gahmj.2015.015.suppl. Epub 2015 Nov 1. Review.

26.

Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.

Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram P, Sehgal V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK.

Clin Cancer Res. 2016 Apr 1;22(7):1713-24. doi: 10.1158/1078-0432.CCR-15-1275. Epub 2015 Nov 18.

27.

Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.

Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL, Lutgendorf SK, Ramirez PT, Sood AK.

Cancer. 2015 Oct 1;121(19):3444-51. doi: 10.1002/cncr.29392. Epub 2015 Aug 24.

28.

Sympathetic nervous system regulation of the tumour microenvironment.

Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK.

Nat Rev Cancer. 2015 Sep;15(9):563-72. doi: 10.1038/nrc3978. Review.

29.

Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.

Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, Rodriguez-Aguayo C, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK.

Oncogene. 2016 May 5;35(18):2390-7. doi: 10.1038/onc.2015.302. Epub 2015 Aug 10.

30.

Effects of Healing Touch and Relaxation Therapy on Adult Patients Undergoing Hematopoietic Stem Cell Transplant: A Feasibility Pilot Study.

Lu DF, Hart LK, Lutgendorf SK, Oh H, Silverman M.

Cancer Nurs. 2016 May-Jun;39(3):E1-E11. doi: 10.1097/NCC.0000000000000272.

PMID:
26098401
31.

Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer.

Davis LZ, Slavich GM, Thaker PH, Goodheart MJ, Bender DP, Dahmoush L, Farley DM, Markon KE, Penedo FJ, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK.

Cancer. 2015 Oct 1;121(19):3543-50. doi: 10.1002/cncr.29516. Epub 2015 Jun 10.

32.

Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma.

Bayer JL, Spitz DR, Christensen D, McCormick ML, Farley D, DeGeest K, Damoush L, Aust S, Sood AK, Lutgendorf SK.

Brain Behav Immun. 2015 Nov;50:58-62. doi: 10.1016/j.bbi.2015.04.019. Epub 2015 May 16.

33.

Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.

Schrepf A, Lutgendorf SK, Pyter LM.

Brain Behav Immun. 2015 Oct;49:1-17. doi: 10.1016/j.bbi.2015.04.010. Epub 2015 May 6. Review.

34.

Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.

Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G.

Oncotarget. 2015 Feb 28;6(6):4266-73.

35.

Biobehavioral approaches to cancer progression and survival: Mechanisms and interventions.

Lutgendorf SK, Andersen BL.

Am Psychol. 2015 Feb-Mar;70(2):186-97. doi: 10.1037/a0035730.

36.

Diurnal cortisol and survival in epithelial ovarian cancer.

Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK.

Psychoneuroendocrinology. 2015 Mar;53:256-67. doi: 10.1016/j.psyneuen.2015.01.010. Epub 2015 Jan 20.

37.

Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: a pilot study.

Bisht B, Darling WG, Shivapour ET, Lutgendorf SK, Snetselaar LG, Chenard CA, Wahls TL.

Degener Neurol Neuromuscul Dis. 2015;5:19-35. doi: 10.2147/DNND.S76523. Epub 2015 Feb 27.

38.

Differential platelet levels affect response to taxane-based therapy in ovarian cancer.

Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, Nick AM, Pradeep S, Zand B, Previs RA, Pecot CV, Crane EK, Hu W, Lutgendorf SK, Afshar-Kharghan V, Sood AK.

Clin Cancer Res. 2015 Feb 1;21(3):602-10. doi: 10.1158/1078-0432.CCR-14-0870. Epub 2014 Dec 3.

39.

The MAPP research network: design, patient characterization and operations.

Landis JR, Williams DA, Lucia MS, Clauw DJ, Naliboff BD, Robinson NA, van Bokhoven A, Sutcliffe S, Schaeffer AJ, Rodriguez LV, Mayer EA, Lai HH, Krieger JN, Kreder KJ, Afari N, Andriole GL, Bradley CS, Griffith JW, Klumpp DJ, Hong BA, Lutgendorf SK, Buchwald D, Yang CC, Mackey S, Pontari MA, Hanno P, Kusek JW, Mullins C, Clemens JQ; MAPP Research Network Study Group.

BMC Urol. 2014 Aug 1;14:58. doi: 10.1186/1471-2490-14-58.

40.

From childhood trauma to elevated C-reactive protein in adulthood: the role of anxiety and emotional eating.

Schrepf A, Markon K, Lutgendorf SK.

Psychosom Med. 2014 Jun;76(5):327-36. doi: 10.1097/PSY.0000000000000072.

41.

Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK.

Cell Rep. 2014 Apr 24;7(2):488-500. doi: 10.1016/j.celrep.2014.03.009. Epub 2014 Apr 3.

42.

A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue.

Bisht B, Darling WG, Grossmann RE, Shivapour ET, Lutgendorf SK, Snetselaar LG, Hall MJ, Zimmerman MB, Wahls TL.

J Altern Complement Med. 2014 May;20(5):347-55. doi: 10.1089/acm.2013.0188. Epub 2014 Jan 29.

43.

Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients.

Lutgendorf SK, Slavich GM, Degeest K, Goodheart M, Bender D, Thaker PH, Penedo F, Zimmerman B, Lucci J 3rd, Mendez L, Collins K, Sood AK.

Gynecol Oncol. 2013 Dec;131(3):667-73. doi: 10.1016/j.ygyno.2013.09.025. Epub 2013 Oct 3.

44.

Impact of cardiovascular comorbidity on ovarian cancer mortality.

Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2102-9. doi: 10.1158/1055-9965.EPI-13-0625. Epub 2013 Sep 17.

45.

Slowing progression of early stages of AD with alternative therapies: a feasibility study.

Lu DF, Hart LK, Lutgendorf SK, Oh H, Schilling M.

Geriatr Nurs. 2013 Nov-Dec;34(6):457-64. doi: 10.1016/j.gerinurse.2013.07.003. Epub 2013 Aug 22.

PMID:
23972540
46.

β-blockers: a new role in cancer chemotherapy?

Nagaraja AS, Sadaoui NC, Lutgendorf SK, Ramondetta LM, Sood AK.

Expert Opin Investig Drugs. 2013 Nov;22(11):1359-63. doi: 10.1517/13543784.2013.825250. Epub 2013 Aug 7.

47.

The effect of healing touch on the pain and mobility of persons with osteoarthritis: a feasibility study.

Lu DF, Hart LK, Lutgendorf SK, Perkhounkova Y.

Geriatr Nurs. 2013 Jul-Aug;34(4):314-22. doi: 10.1016/j.gerinurse.2013.05.003. Epub 2013 Jul 5.

PMID:
23835011
48.

Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis.

Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci J 3rd, Thaker PH, Mendez L, Sood AK, Slavich GM, Lutgendorf SK.

Cancer. 2013 Sep 1;119(17):3234-41. doi: 10.1002/cncr.28188. Epub 2013 Jun 24.

49.

Biologic effects of dopamine on tumor vasculature in ovarian carcinoma.

Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK.

Neoplasia. 2013 May;15(5):502-10.

50.

Src activation by β-adrenoreceptors is a key switch for tumour metastasis.

Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK.

Nat Commun. 2013;4:1403. doi: 10.1038/ncomms2413. Erratum in: Nat Commun. 2013;4:1932. Shazhad, Mian M K [corrected to Shahzad, Mian M K].

Supplemental Content

Loading ...
Support Center